CN102170916A - 环境活化的组合物，制品与方法 - Google Patents
环境活化的组合物，制品与方法 Download PDFInfo
- Publication number
- CN102170916A CN102170916A CN2009801390187A CN200980139018A CN102170916A CN 102170916 A CN102170916 A CN 102170916A CN 2009801390187 A CN2009801390187 A CN 2009801390187A CN 200980139018 A CN200980139018 A CN 200980139018A CN 102170916 A CN102170916 A CN 102170916A
- Authority
- CN
- China
- Prior art keywords
- goods
- paster
- band
- layer
- rete
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title description 20
- 239000000203 mixture Substances 0.000 title description 16
- 229920002413 Polyhexanide Polymers 0.000 claims abstract description 14
- 102000008186 Collagen Human genes 0.000 claims abstract description 12
- 108010035532 Collagen Proteins 0.000 claims abstract description 12
- 229920001436 collagen Polymers 0.000 claims abstract description 12
- 239000000853 adhesive Substances 0.000 claims abstract description 11
- 230000001070 adhesive effect Effects 0.000 claims abstract description 11
- 239000004599 antimicrobial Substances 0.000 claims abstract description 9
- 239000000017 hydrogel Substances 0.000 claims abstract description 7
- 230000000845 anti-microbial effect Effects 0.000 claims description 37
- 239000000463 material Substances 0.000 claims description 26
- -1 cationic quaternary ammonium compound Chemical class 0.000 claims description 15
- 239000000835 fiber Substances 0.000 claims description 14
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000006260 foam Substances 0.000 claims description 10
- 150000003863 ammonium salts Chemical group 0.000 claims description 8
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 239000005038 ethylene vinyl acetate Substances 0.000 claims description 5
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 239000004814 polyurethane Substances 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 229920000615 alginic acid Polymers 0.000 claims description 3
- 235000010443 alginic acid Nutrition 0.000 claims description 3
- 229920001971 elastomer Polymers 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 230000007246 mechanism Effects 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims description 2
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940123208 Biguanide Drugs 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001768 cations Chemical class 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229920000098 polyolefin Polymers 0.000 claims description 2
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 claims description 2
- 229920002994 synthetic fiber Polymers 0.000 claims description 2
- 239000012209 synthetic fiber Substances 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001059 synthetic polymer Polymers 0.000 claims 1
- 206010052428 Wound Diseases 0.000 description 18
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 239000010408 film Substances 0.000 description 18
- 239000010409 thin film Substances 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000004925 Acrylic resin Substances 0.000 description 3
- 229920000178 Acrylic resin Polymers 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
- 102000013275 Somatomedins Human genes 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000009954 braiding Methods 0.000 description 3
- 206010061592 cardiac fibrillation Diseases 0.000 description 3
- 238000005660 chlorination reaction Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000002600 fibrillogenic effect Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000031709 bromination Effects 0.000 description 2
- 238000005893 bromination reaction Methods 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- YIOJGTBNHQAVBO-UHFFFAOYSA-N dimethyl-bis(prop-2-enyl)azanium Chemical compound C=CC[N+](C)(C)CC=C YIOJGTBNHQAVBO-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000003357 wound healing promoting agent Substances 0.000 description 2
- IWYNVAJACBPVLT-UHFFFAOYSA-N 1-[10-(4-amino-2-methylquinolin-1-ium-1-yl)decyl]-2-methylquinolin-1-ium-4-amine;diacetate Chemical compound CC([O-])=O.CC([O-])=O.C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 IWYNVAJACBPVLT-UHFFFAOYSA-N 0.000 description 1
- WFENCVFYUBXRSH-UHFFFAOYSA-N 1-dodecyl-2-methylquinolin-1-ium-4-amine;acetate Chemical compound CC([O-])=O.C1=CC=C2[N+](CCCCCCCCCCCC)=C(C)C=C(N)C2=C1 WFENCVFYUBXRSH-UHFFFAOYSA-N 0.000 description 1
- AOAQBXAGGBSALU-UHFFFAOYSA-N 2-[2-[dodecanoyl(methyl)amino]ethyl-dimethylazaniumyl]-n-phenylethanimidate;hydrochloride Chemical compound [Cl-].CCCCCCCCCCCC(=O)N(C)CC[N+](C)(C)CC(=O)NC1=CC=CC=C1 AOAQBXAGGBSALU-UHFFFAOYSA-N 0.000 description 1
- KUXUALPOSMRJSW-IFWQJVLJSA-N 2-[6-[[amino-[[amino-(4-chloroanilino)methylidene]amino]methylidene]amino]hexyl]-1-[amino-(4-chloroanilino)methylidene]guanidine;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 KUXUALPOSMRJSW-IFWQJVLJSA-N 0.000 description 1
- CBYAPCMTYUIARL-UHFFFAOYSA-N 4-phenylbut-3-en-1-amine Chemical compound NCCC=CC1=CC=CC=C1 CBYAPCMTYUIARL-UHFFFAOYSA-N 0.000 description 1
- GQCIBLGQUDFKGX-WLHGVMLRSA-M 5-amino-2-[(e)-2-(4-amino-2-sulfophenyl)ethenyl]benzenesulfonate;(2,4-dichlorophenoxy)methyl-dimethyl-octylazanium Chemical compound CCCCCCCC[N+](C)(C)COC1=CC=C(Cl)C=C1Cl.OS(=O)(=O)C1=CC(N)=CC=C1\C=C\C1=CC=C(N)C=C1S([O-])(=O)=O GQCIBLGQUDFKGX-WLHGVMLRSA-M 0.000 description 1
- JMTNOKRGERWNME-UHFFFAOYSA-L 6-[dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azaniumyl]hexyl-dimethyl-[4-(2,2,6-trimethylcyclohexyl)butan-2-yl]azanium;dichloride Chemical compound [Cl-].[Cl-].CC1CCCC(C)(C)C1CCC(C)[N+](C)(C)CCCCCC[N+](C)(C)C(C)CCC1C(C)CCCC1(C)C JMTNOKRGERWNME-UHFFFAOYSA-L 0.000 description 1
- 229920002955 Art silk Polymers 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 241001649247 Boehmeria Species 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 108050004290 Cecropin Proteins 0.000 description 1
- 244000146553 Ceiba pentandra Species 0.000 description 1
- 235000003301 Ceiba pentandra Nutrition 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 235000010206 Corchorus olitorius Nutrition 0.000 description 1
- 244000227473 Corchorus olitorius Species 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- JGFDZZLUDWMUQH-UHFFFAOYSA-N Didecyldimethylammonium Chemical compound CCCCCCCCCC[N+](C)(C)CCCCCCCCCC JGFDZZLUDWMUQH-UHFFFAOYSA-N 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 229920000271 Kevlar® Polymers 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108060003100 Magainin Proteins 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 229920002821 Modacrylic Polymers 0.000 description 1
- 240000000907 Musa textilis Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229920006221 acetate fiber Polymers 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000000964 angiostatic effect Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- QDYLMAYUEZBUFO-UHFFFAOYSA-N cetalkonium chloride Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 QDYLMAYUEZBUFO-UHFFFAOYSA-N 0.000 description 1
- 229960000228 cetalkonium chloride Drugs 0.000 description 1
- 229960002798 cetrimide Drugs 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229950007585 chlorphenoctium amsonate Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 229960001378 dequalinium chloride Drugs 0.000 description 1
- LTNZEXKYNRNOGT-UHFFFAOYSA-N dequalinium chloride Chemical compound [Cl-].[Cl-].C1=CC=C2[N+](CCCCCCCCCC[N+]3=C4C=CC=CC4=C(N)C=C3C)=C(C)C=C(N)C2=C1 LTNZEXKYNRNOGT-UHFFFAOYSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940078672 didecyldimethylammonium Drugs 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229950011018 dofamium chloride Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000012992 electron transfer agent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009950 felting Methods 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 229940035535 iodophors Drugs 0.000 description 1
- 239000004761 kevlar Substances 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229950004179 laurolinium acetate Drugs 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 108010062940 pexiganan Proteins 0.000 description 1
- KGZGFSNZWHMDGZ-KAYYGGFYSA-N pexiganan Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 KGZGFSNZWHMDGZ-KAYYGGFYSA-N 0.000 description 1
- 229950001731 pexiganan Drugs 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229920006298 saran Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0213—Adhesive bandages or dressings with fluid retention members the fluid retention member being a layer of hydrocolloid, gel forming material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0203—Adhesive bandages or dressings with fluid retention members
- A61F13/0226—Adhesive bandages or dressings with fluid retention members characterised by the support layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
- A61F13/0246—Adhesive bandages or dressings characterised by the skin-adhering layer
- A61F13/0253—Adhesive bandages or dressings characterised by the skin-adhering layer characterized by the adhesive material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
- A61L15/325—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/58—Adhesives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00412—Plasters use for use with needles, tubes or catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00846—Plasters with transparent or translucent part
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/114—Nitric oxide, i.e. NO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
- A61L2300/608—Coatings having two or more layers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Laminated Bodies (AREA)
Abstract
制品(10)包括膜层(12)；在膜层的至少一面上的至少一层粘合剂(13)，含至少一种抗微生物剂的贴片或条带(14)，该贴片或条带置于与至少一层粘合剂相同的膜层侧上；和可剥离地固定到与贴片或条带相对的膜层一侧上的相对非挠性的片材(16)。或者制品(10`)包括膜层(28)；胶原层(24)；和含PHMB的可生物降解的水凝胶层(26)；其中在膜层和胶原层之间布置含PHMB的可生物降解的水凝胶层。还公开了含有这些制品的伤口敷料(10，10`)。
Description
发明领域
本发明涉及抗微生物组合物，制品和方法。
发明背景
在其中提到或讨论文献、学位论文或知识信息(item of knowledge)的本说明书中，这一种提到或讨论不是承认该文献、学位论文或知识信息或其任何结合在优先权日时，公众可获知，公众公知，是普通技术知识的一部分，或者在其他情况下，根据合适的法律规定，构成现有技术；或者已知与尝试解决本说明书所涉及的任何问题有关。
提出了各种抗微生物组合物，制品和方法。然而，这种伤口组合物和方法具有各种缺陷和缺点。
薄膜敷料用于宽范围的应用中。在它们的各种结构中，它们用于皮肤的撕裂、IV或导尿管固定敷料附着和外科手术位点上。然而，许多常规薄膜敷料对防止位点感染不起作用。一些薄膜敷料正在进入市场，宣称提供对微生物繁殖和感染的阻止。各自不同地接近该课题。一种可商购的产物掺混碘附到粘合剂内。另一产品为吸附剂圆盘形式，所述浸渍有葡萄糖酸洗必太的吸附剂圆盘用薄膜敷料保持就位。再一产品提供其中离子银掺混到粘合剂与薄膜内的敷料。
然而，本领域仍需要在减少和/或防止形成不想要的微生物有机物方面的有效性增加，安全并提供伤口护理控制效率改进的组合物、装置和方法。
尽管讨论了常规技术的一些方面有助于理解本发明的公开内容，但申请人决不否认这些技术方面，且认为要求保护的发明可包括此处讨论的一个或更多个常规技术性方面。
定义
除非另有说明，此处所使用的术语“微生物有机物”或“微生物”用于指代微小的有机物，其中包括真菌，细菌和/或病毒有机物。因此，此处所使用的术语“抗微生物剂”是指杀灭或在其他情况下抑制这种真菌、细菌和/或病毒有机物生长的组合物或试剂。
发明概述
本发明可解决以上讨论的现有技术中的一个或更多个问题和缺陷。然而，认为本发明被证明可用于解决其他问题和缺陷，或者在许多技术领域中提供优势和优点。因此，要求保护的发明不应当必然解释为限制到解决此处讨论的任何特定问题或缺陷上。
本发明可任选地具有一个或更多个以下的优势或优点：(i)显示出提高的抗微生物性能的组合物、层压体和方法；(ii)对人类给药来说有效且安全以及可容易获得的组合物、层压体和方法；和(iii)能更加有效地进行伤口护理管理的组合物、层压体和方法。
本发明也可任选地具有一个或更多个下述特征、优势和/或优点。
组合物或伤口敷料的目的在于在整个包扎区域上对特定区域具有抗微生物活性。
可程序释放的抗微生物剂。当使用多层时，具有起始爆发接着持续释放的曲线将有益地减少起始的细菌负载，然后提供连续保护。
凝胶形成作用将控制管线泄漏并在IV或导尿管插入区域内提供无痛除去。
构造敷料，以便允许单独一人递送。
使用PHMB的组合物、制品或方法。PHMB对正常的皮肤菌群无害，因此没有干扰上皮形成。PHMB用作日常预防药是足够成本低廉的。PHMB在超过60年的常见使用中不具有已知的抗性；这允许它用于每一伤口上且不具有大的抗性危险。
透明敷料，因此临床医师能看到伤口/出口(exit)位点。市场上的其他产品在视觉上阻断了该位点，因此为了彻底观察到该位点，要求更换敷料。条带和敷料的透明性质将减少敷料的更换，因为位点/伤口可容易观察到。
一种敷料，它包括基于伤口内的湿气溶解的薄膜。该薄膜可以透气，从而允许伤口在愈合过程中的透气性。可配制该薄膜，以便当润湿时，它将粘附到皮肤和伤口上，且不需要额外的粘合剂，从而使得敷料的更换对患者皮肤的创伤较少。
在伤口位点处控制微生物水平优化可生物降解的含胶原的敷料的影响。
根据一个方面，本发明提供一种制品，它包括薄膜层；在薄膜层的至少一侧上的至少一层粘合剂；含至少一种抗微生物剂的贴片(patch)或条带，该贴片或条带分布在与至少一层粘合剂相同的薄膜侧；和可剥离地固定到与贴片或条带相对的薄膜侧上的相对非挠性的片材。
根据额外的方面，本发明提供一种制品，它包括：薄膜层；胶原层；和含PHMB的可生物降解的水凝胶层；其中含PHMB的可生物降解的水凝胶层置于薄膜层和胶原层之间。
根据额外的方面，本发明提供由任何一种以上提及的制品形成的伤口敷料。
附图简述
图1是根据本发明原理形成的层压体/敷料的截面示意图。
图2是本发明层压体/敷料组件的一个实施方案的截面示意图。
图3是本发明的层压体/敷料的替代实施方案的截面示意图。
图4是图3的层压体/敷料的替代实施方案的顶视图。
图5是根据本发明进一步的实施方案形成的层压体/敷料的顶视图。
图6是根据本发明额外的实施方案形成的层压体/敷料的截面示意图。
图7是根据本发明再一实施方案形成的层压体/敷料的截面示意图。
图8是图7的层压体/敷料的改性方案或替代实施方案的截面示意图。
图9是根据本发明形成的层压体/敷料的再一实施方案的截面示意图。
详细说明
根据一实施方案，本发明可提供组合物、方法或新型薄膜层压体或伤口敷料的形式，它们将提供抗微生物剂的靶向释放。
可使用任何合适的薄膜材料。该薄膜可由任何数量的亲水或疏水材料或在其他情况下将提供充足贴合性(conformability)和适合于打算最终用途的湿气渗透率(MVTR)的聚合物制成。有用的可能的聚合物的实例是：聚酯聚氨酯，聚醚聚氨酯，聚烯烃，EVA，PVC和茂金属。薄膜和/或整个层压体或敷料可以基本上透明，其程度至少使得允许视觉检查在其下方的皮肤表面。薄膜和/或敷料可具有任何合适的几何形状和/或尺寸。例如，薄膜敷料可包括薄(0.0005英寸-0.0015英寸)的挠性薄膜。
类似地，可使用任何合适的抗微生物剂。例如，聚合的双胍，例如PHMB，PEHMB或其衍生物可用作抗微生物剂。或者，一些金属，或含这些金属，例如银、金、铜或锌的化合物可用作抗微生物剂。另外认为抗微生物处理可以是许多试剂，例如银、PHMB、CHG、EDTA或其他合适的抗微生物剂的组合，以便实现协同效应。
根据一些实施方案，抗微生物剂可包括阳离子表面活性剂或阳离子季铵化合物。这些化合物的非限定性实例包括：氯化苄烷铵，氯化苄乙铵；溴化十四烷基三甲基铵；氯化十六烷基吡啶；安索氯芬铵；醋酸克菌定；地喹氯铵；溴化度米芬；醋酸氨月甲喹；氯化甲苄乙氧铵；氯甲十四烷基吡啶；ortaphnum chloride；创必龙；西他氯铵；氯化杜法铵；溴化四乙铵；氯化二癸基二甲铵；溴化四乙铵；氯化二甲基二烯丙基铵；对三烷基氨乙基苯乙烯单体；和三烷基(对乙烯基苄基)氯化铵。
根据进一步的实施方案，抗微生物剂可包括阳离子表面活性剂或聚合的季铵化合物。这些化合物的非限定性实例包括：聚(氯化二烯丙基二甲铵)；聚(3-氯-2-羟丙基)甲基丙烯酰氧基乙基二甲基氯化铵；聚(丙烯酰胺-甲基丙烯酰氧基乙基三甲基溴化铵)；聚(丙烯酸丁酯-甲基丙烯酰氧基乙基三甲基溴化铵)；聚(1-甲基-4-乙烯基溴化吡啶)；聚(1-甲基-2-乙烯基溴化吡啶)；和聚(甲基丙烯酰氧基乙基三乙基溴化铵)。
根据额外的替代实施方案，抗微生物剂可包括聚季铵盐(polyquaternium)。聚季铵盐是强调在聚合物内存在季铵中心而使用的新字。聚季铵盐荷正电，一些具有抗微生物性能。目前存在至少37种聚季铵盐牌号的不同的已知聚合物。定期地鉴定新的聚季铵盐。不同的聚合物的通过在措辞“聚季铵盐”之后紧跟的数值来鉴别。因此，本发明考虑可能使用任何目前已知的聚季铵盐-1到聚季铵盐-37的物质，以及目前没有牌号，落在以上所述的宽的定义或分类内的将来的聚季铵盐。
根据进一步的实施方案，抗微生物剂可包括阳离子抗微生物肽，例如e-聚-1-赖氨酸，爪蟾抗菌肽，蛾血素，皮抑菌肽，培西加南，艾塞加南，Oniganan和防卫素。
根据额外的替代方案，抗微生物剂可包括两性表面活性剂，例如包括烷基甜菜碱，十二烷基甜菜碱，椰油两性氨基乙酸盐(cocoamphoglycinate)和椰油酰胺基丙基甜菜碱。
根据进一步的实施方案，抗微生物剂可包括溴基化合物，例如聚(4-乙烯基-N-烷基溴化吡啶)；和聚(4-乙烯基-N-己基溴化吡啶)。
如图1所示，根据进一步的实施方案，组合物，方法或层压体或敷料10除了包括至少一种前述膜层12以外，可包括含有任何合适抗微生物剂，例如以上所述的那些的至少一个贴片或条带14。
可由任何合适的材料或材料的组合形成贴片或条带14。例如，贴片或条带可包括编织和/或非编织纤维。合适的纤维可包括天然纤维，合成纤维，或其组合。因此，可由金属，陶瓷，聚合物或天然材料形成合适的纤维。非限定性实例包括棉、纤维素、聚酯、聚乙烯、聚丙烯、PTFE、尼龙、芳族聚酰胺纤维、Kevlar、壳聚糖、藻酸盐(酯)、聚(对苯二甲酸乙二酯)(PET)、丙烯酸树脂、氟烃、变性聚丙烯腈纤维、聚酯、橡胶、偏氯纶树脂、斯潘德克斯弹力纤维、维纳尔、维尼昂、人造丝、醋酯纤维、三醋酯纤维、蛋白质、亚麻、大麻、黄麻、苎麻、蕉麻(manila)、木棉、羊毛或蚕丝。
纤维可具有任何合适的尺寸，例如从5nm到5mm的有效直径，和比表面积可以从0.001变化到1000m2/g。纤维的截面可以是三角形，圆形，原纤化(fibrillated)或4DGTM(商购于Fiber InnovationTechnology，Inc.，Johnson City，TN；还参见Heather L.Paul等人，“Comparison of Thermal Insulation Performance of FibrousMaterials for the Advanced Space Suit”，Journal of BiomechanicalEngineering，Volume 125，2003年10月，第639-647页；全部内容在此通过参考引入)；或任何其他形状。
可按照任何合适的方式组合纤维，例如编织、非编织、针织、毡缩(felt)或编织纤维。纤维可以是连续纤维或纤维束，短切纤维，湿法成网/纸张、熔喷、急骤纺丝原纤化胶带、纺粘、针刺、梳理、复合结构、热粘结、化学粘结、水力缠结、气流成网、干法成网、高蓬松度、超声粘结、缝编或粉末粘合剂粘结。
贴片或条带14可包括泡沫。这一泡沫可由聚氨酯、烯烃、PVC、聚丙烯、聚乙烯、EVA、ESI、或其他聚合物组成。泡沫可以是珠状气体形成的泡沫或通过任何其他合适的方法形成的泡沫。该泡沫可以是具有5-200个孔/英寸(ppi)的开孔或闭孔。可通过热、碱或其他网状方式，形成闭孔泡沫。该泡沫的密度可以是从1变化到5lb/ft3。
贴片或条带14也可包括聚合物膜。这一膜可由许多合成、人造或天然聚合物组成。该膜可以打孔或原纤化。
可基于环境条件来活化含抗微生物剂的贴片或条带14。活化包括至少部分释放抗微生物剂。已知活化模式是湿气。目前在透气性条带、个人产品和药物中使用湿气反应性膜技术。其他可能的活化机理包括快速溶解或崩解在条带内的赋形剂；pH；酶；巨噬细胞；离子强度；湿气；和温度。可配制具有各种水平灵敏度、厚度和/或各种抗微生物剂浓度的含抗微生物剂的贴片或条带14。因此，贴片或条带14可提供有不同的抗微生物剂洗脱率。
根据替代的实施方案，至少一层膜层可提供有印刷或其他标记(未示出)，以鉴定产品，活性成分，货架期，预期的抗微生物寿命等。
根据额外的替代实施方案，层压体/敷料10可在其至少一面上提供有至少一层粘合剂13。含抗微生物剂的贴片或条带14可策略地放置在薄膜敷料10的粘合剂侧上。通过打算的最终用途或应用，决定精确的位置。可通过本领域技术人员已知的许多技术中的任何一种，施加粘合剂13和/或贴片或条带14。可使用任何合适的粘合剂材料。取决于应用，可使用丙烯酸类树脂，PIB橡胶和硅酮粘合剂。可任选地通过保护性可剥离纸或塑料片材(未示出)覆盖粘合剂13。
根据进一步的替代实施方案，至少一种贴片或条带14可按照任何已知的方式(未示出)用抗微生物剂涂布的硅酮片材或者用抗微生物剂处理的非编织织物或层压体薄膜替代，或者进行补充(complimented)。
如图2所示，含抗微生物剂的贴片或条带14可包括多层(14a，14b，14c，14d)，一层或更多层可具有不同的抗微生物剂洗脱率和/或不同的活性成分和/或不同的抗微生物剂。对伤口愈合有益的合适的活性成分的非限定性实例包括止痛药，维生素，生长因子，止血剂，和抗微生物剂等。一种可能的多层组合可提供活性成分，例如抗微生物剂、止痛药、生长因子等的按序释放。
除了提供目标的抗微生物释放以外，也可采用吸收剂凝胶形成材料，例如，但不限于，聚环氧乙烷，藻酸盐(酯)，羧甲基纤维素(CMC)，聚乙烯吡咯烷酮(PVP)，和交联的丙烯酸类树脂一起配制贴片或条带14。也可采用影响伤口愈合过程的生物材料配制贴片或条带14。实例包括交联的胶原和透明质酸。贴片或条带14也可含有一旦活化则生成抗微生物剂和/或影响伤口愈合过程的材料的这种材料。实例包括氧化氮(nitric oxide)生成化合物。还将预见条带的配制可包括螯合剂以提高抗微生物剂的性能。合适的螯合剂包括，但不限于EDTA。
例如如图3所示，根据进一步的替代实施方案，层压体/敷料10可提供有充足刚度的任选片材16，以促进完全的层压体/敷料10的“单手(one handed)”施加。
可由具有所需劲度的任何合适的材料形成片材16。例如，可由聚合物形成片材16。合适的聚合物的一种非限定性实例是乙烯乙酸乙烯酯。
根据所示的实施方案，将片材16附着到膜12的与粘合剂13相对的一面上。可使用任何合适的技术附着片材16到膜12上。例如，在美国专利No.4600001中阐述了一种合适的技术，其全部内容在此通过参考引入。因此，片材16可以是基本上透明和/或可剥离地附着到膜12上。
对于非导尿管应用来说，可除去片材16的中心区域17，提供加强的挠性和改进的清澈度，使得通过层压体/敷料10看到伤口(图4)。对于一些应用，例如P1CC线，中线，中心静脉导管，和渗析导管来说，被除去的中心部分可以缩减并位于敷料的一侧上，以便在敷料内开窗(未示出)。观察窗和/或开窗的定位和大小可根据最终用途而变化。类似地，层压体/敷料10可包括通过所有层的冲切部分，以便有助于插入导管或IV装置。
例如如图5所示，层压体/敷料10可在薄膜敷料与粘合剂的边缘上方紧固的敷料四周进一步提供泡沫、凝胶或织物类型支撑垫18。该垫子将防止皮肤受导管/IV装置的刺激。而且，条带或额外的粘合剂片可将导管固定到膜上而不是皮肤上(未示出)。
根据本发明的额外实施方案，可构造层压体/敷料10，以便在膜12和贴片或条带14之间不存在粘合剂13。图6中示出了这一实施方案的一个实例。在更换敷料的情况下，这一构造允许对受伤区域的创伤最小。
根据本发明原理形成的层压体/敷料10也可包括一片泡沫20，或者对于不同目的来说，例如对于导管22的出口和吸收来说，可提供另一吸收剂材料，以增加缓冲，如图7所示。贴片或条带14可位于皮肤侧21(图7)或膜12侧(图8)，其中它将充当微生物的阻挡层。
如上所述，层压体/敷料除了含有一种或更多种抗微生物剂以外，还可含有其他伤口愈合剂。例如，层压体/敷料10可含有可生物降解的胶原和PHMB，以控制在其内的微生物水平，防止伤口感染。如图9所示，根据一个例举的实施方案，根据本发明原理形成的层压体/敷料10`可包括夹在为了控制伤口内微生物水平的含PHMB的可生物降解水凝胶26和为了控制外部污染的外部膜层28之间的胶原层24。可由任何合适的材料形成外部膜层。例如，可由与膜层12相关的以上所述的相同材料形成膜层28。
伤口敷料当然可包括额外的活性成分或试剂，例如治疗剂、特殊感觉剂(organoleptic agent)，生长因子，止痛药，组织支架剂、止血剂、蛋白质抑制剂，胶原，酶，抗血栓剂，麻醉药，消炎药，抗癌剂，血管舒张物质，伤口愈合剂，血管生成剂，血管抑制(angiostatic)剂，免疫促进剂，皮肤封闭剂，诱导定向细菌生长的试剂，赋予杀菌或抑菌活性的试剂，使微生物的新陈代谢作用和/或生物膜形成去稳定或破坏的电子转移试剂，其组合和类似物。可通过各种方式，例如电场或信号、温度、时间、压力、湿气、光(例如，紫外光)、超声能、超声、其组合和类似方式，触发活性试剂的释放。
表达在本说明书中所使用的各成分、组成、反应条件等等用量的任何数值应当理解为在所有情况下用术语“约”修饰。尽管列出了数值范围和参数，但此处列出的主题的宽范围是近似值，所列出的数值尽可能精确地表示。然而，任何数值可固有地包含一定的误差或不确定性，这根据它们各自的测量技术中发现的标准偏差看出。此处引证的特征无一应当解释为援引35U.S.C.§112，6，除非明确地使用术语“方式(means)”。
尽管结合本发明的优选实施方案描述了本发明，但本领域的技术人员要理解，可在没有脱离本发明的精神和范围的情况下，做出没有具体地描述的增加，删除，改性和替代。
Claims (16)
1.一种制品，它包括：
膜层；
在该膜层的至少一面上的至少一层粘合剂；
含至少一种抗微生物剂的贴片或条带，该贴片或条带布置在与所述至少一层粘合剂相同的膜层一侧上；和
可剥离地附着到与贴片或条带相对的膜层一侧上的相对非挠性片材。
2.权利要求1的制品，其中相对非挠性片材基本上透明。
3.权利要求3的制品，其中非挠性片材包括在其内形成的窗口。
4.权利要求1的制品，进一步包括置于制品周围上的支撑垫。
5.权利要求1的制品，进一步包括置于贴片或条带至少一面上的至少一层泡沫层。
6.权利要求5的制品，其中泡沫层布置在贴片或条带和所述至少一层粘合剂之间，或者在泡沫层和所述至少一层粘合剂之间。
7.权利要求1的制品，其中膜层包括聚酯聚氨酯，聚醚聚氨酯，聚烯烃，EVA，PVC或茂金属，和其中膜层的厚度为约0.0005英寸-约0.0015英寸。
8.权利要求1的制品，其中至少一种抗微生物剂包括：聚合的双胍，阳离子季铵化合物，聚合的季铵化合物，聚季铵盐，阳离子抗微生物肽，或其组合，其中贴片或条带包括：天然纤维，合成纤维，泡沫，天然聚合物，合成聚合物，或其组合，其中贴片或条带提供有释放至少一种抗微生物剂的活化机构，该活化机构包括湿气，溶解或崩解赋形剂，pH，酶，巨噬细胞，离子强度，湿气，和温度；和其中粘合剂包括丙烯酸类，PIB橡胶或硅酮。
9.权利要求1的制品，其中贴片或条带包括多层。
10.权利要求9的制品，其中构造贴片或条带按序释放活性成分。
11.权利要求1的制品，其中贴片或条带包括聚环氧乙烷，藻酸盐(酯)，羧甲基纤维素，聚乙烯吡咯烷酮，交联的丙烯酸，胶原或透明质酸；和其中贴片或条带进一步包括生成一氧化氮的化合物或螯合剂。
12.权利要求1的制品，其中相对非挠性的片材包括乙烯乙酸乙烯酯。
13.权利要求1的制品，其中在贴片或条带与膜层之间不存在粘合剂。
14.一种伤口敷料，它包括权利要求1的制品。
15.一种制品，它包括：
膜层；
胶原层；和
含PHMB的可生物降解的水凝胶层；
其中在膜层和胶原层之间布置含PHMB的可生物降解的水凝胶层。
16.一种伤口敷料，它包括权利要求15的制品。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13632008P | 2008-08-28 | 2008-08-28 | |
| US61/136,320 | 2008-08-28 | ||
| PCT/US2009/004908 WO2010024928A1 (en) | 2008-08-28 | 2009-08-28 | Environmentally activated compositions, articles and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102170916A true CN102170916A (zh) | 2011-08-31 |
Family
ID=41721810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801390187A Pending CN102170916A (zh) | 2008-08-28 | 2009-08-28 | 环境活化的组合物，制品与方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20100055158A1 (zh) |
| EP (1) | EP2323703A4 (zh) |
| CN (1) | CN102170916A (zh) |
| AU (1) | AU2009286021B2 (zh) |
| WO (1) | WO2010024928A1 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853590A (zh) * | 2018-08-22 | 2018-11-23 | 上海长海医院 | 一种人工真皮 |
| CN111432761A (zh) * | 2017-11-03 | 2020-07-17 | 凯希特许有限公司 | 延长穿戴时间的敷料 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
| GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
| GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
| US7569742B2 (en) | 2005-09-07 | 2009-08-04 | Tyco Healthcare Group Lp | Self contained wound dressing with micropump |
| US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
| DE102010020050A1 (de) | 2010-05-11 | 2011-11-17 | Ivf Hartmann Ag | Wundauflage |
| US9095558B2 (en) | 2010-10-08 | 2015-08-04 | Board Of Regents, The University Of Texas System | Anti-adhesive barrier membrane using alginate and hyaluronic acid for biomedical applications |
| WO2012048283A1 (en) | 2010-10-08 | 2012-04-12 | Board Of Regents, The University Of Texas System | One-step processing of hydrogels for mechanically robust and chemically desired features |
| CZ22394U1 (cs) * | 2011-03-11 | 2011-06-20 | Contipro C, A.S. | Antimikrobiální smes a kryt pro podporu hojení ran s antimikrobiálním úcinkem |
| US8708981B2 (en) | 2011-05-26 | 2014-04-29 | Kci Licensing, Inc. | Systems and methods of stimulation and activation of fluids for use with instillation therapy |
| US20120310186A1 (en) * | 2011-06-06 | 2012-12-06 | Tyco Healthcare Group Lp | Dressings and Related Methods Therefor |
| EP3508182A1 (en) | 2011-07-14 | 2019-07-10 | Smith & Nephew PLC | Wound dressing and method of treatment |
| CA2856230C (en) * | 2011-12-07 | 2020-12-08 | Kci Licensing, Inc. | Synthetic granulating gauze for use with reduced-pressure treatment systems |
| CN107260399B (zh) | 2012-03-12 | 2022-02-22 | 史密夫及内修公开有限公司 | 用于减压伤口治疗的伤口敷料装置 |
| WO2013167671A2 (de) | 2012-05-08 | 2013-11-14 | Nolax Ag | Verfahren zur herstellung einer zwei-komponenten-polyurethanzusammensetzung umfassend ein oder mehrere in polaren lösungsmitteln lösliche additive |
| JP6400570B2 (ja) | 2012-05-23 | 2018-10-10 | スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ | 局所陰圧閉鎖療法のための装置および方法 |
| MX353782B (es) | 2012-08-01 | 2018-01-29 | Smith & Nephew | Apósito para heridas. |
| US10076449B2 (en) | 2012-08-01 | 2018-09-18 | Smith & Nephew Plc | Wound dressing and method of treatment |
| US11565027B2 (en) | 2012-12-11 | 2023-01-31 | Board Of Regents, The University Of Texas System | Hydrogel membrane for adhesion prevention |
| EP4253454A3 (en) * | 2012-12-11 | 2024-01-03 | Board of Regents, The University of Texas System | Hydrogel membrane for adhesion prevention |
| CN106659590B (zh) | 2014-06-18 | 2020-08-21 | 史密夫及内修公开有限公司 | 伤口敷料 |
| DE102015206083A1 (de) | 2015-04-02 | 2016-10-06 | Ivf Hartmann Ag | Wundauflage zur Wundbehandlung im feuchten oder feuchtnassen Milieu |
| IT201600093678A1 (it) * | 2016-09-19 | 2018-03-19 | Federico Pecorari | Medicazione emostatica per accesso vascolare |
| GB2555584B (en) | 2016-10-28 | 2020-05-27 | Smith & Nephew | Multi-layered wound dressing and method of manufacture |
| WO2018165327A1 (en) | 2017-03-08 | 2018-09-13 | Alafair Biosciences, Inc. | Hydrogel medium for the storage and preservation of tissue |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049182A1 (en) * | 2001-08-21 | 2005-03-03 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| US20070237812A1 (en) * | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
| US20080063695A1 (en) * | 2006-09-12 | 2008-03-13 | Tyco Healthcare Group Lp | Thin film dressing |
| CN101252905A (zh) * | 2005-07-15 | 2008-08-27 | 泰科保健集团有限合伙公司 | 伤口敷料和制造及使用其的方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579628A (en) * | 1967-07-03 | 1971-05-18 | Johnson & Johnson | Dressing film |
| US3983209A (en) * | 1975-01-28 | 1976-09-28 | Alza Corporation | Method for treating burns |
| DE3423328A1 (de) * | 1984-06-23 | 1986-01-02 | Beiersdorf Ag, 2000 Hamburg | Selbstklebendes pflaster |
| US4600001A (en) * | 1984-08-15 | 1986-07-15 | The Kendall Company | Combined wound dressing and delivery means composite |
| US4643180A (en) * | 1985-02-28 | 1987-02-17 | Surgikos, Inc. | Antimicrobial dressing |
| JPS62169723A (ja) * | 1986-01-22 | 1987-07-25 | Teisan Seiyaku Kk | 徐放化製剤 |
| US4759354A (en) * | 1986-11-26 | 1988-07-26 | The Kendall Company | Wound dressing |
| US4830856A (en) * | 1987-01-27 | 1989-05-16 | Peppers James M | Chelation product |
| GB2272645B8 (en) * | 1992-11-23 | 2010-02-10 | Johnson & Johnson Medical | Wound dressing |
| DE19503336C2 (de) * | 1995-02-02 | 1998-07-30 | Lohmann Therapie Syst Lts | Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US5674523A (en) * | 1995-09-01 | 1997-10-07 | New Dimensions In Medicine, Inc. | Self-adhesive hydrogel wound dressing |
| US20020015726A1 (en) * | 2000-06-30 | 2002-02-07 | Scamilla Aledo Maria Aparecida De Carvalho | Dressings and bandages comprising same |
| MXPA02008606A (es) * | 2000-03-10 | 2003-04-14 | 3M Innovative Properties Co | Vendajes medicos con adhesivos multiples y metodos de elaboracion. |
| US7137968B1 (en) | 2000-03-13 | 2006-11-21 | Nucryst Pharmaceuticals Corp. | Transcutaneous medical device dressings and method of use |
| US6719987B2 (en) * | 2000-04-17 | 2004-04-13 | Nucryst Pharmaceuticals Corp. | Antimicrobial bioabsorbable materials |
| US6399092B1 (en) * | 2000-12-27 | 2002-06-04 | Healthpoint, Ltd. | Anhydrous, hydrophilic absorbent wound dressing (tube) with antimicrobials or other pharmaceutically active agents |
| US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
| US7704523B2 (en) * | 2002-04-26 | 2010-04-27 | Lohmann & Rauscher Gmbh | Microbial cellulose wound dressing for treating chronic wounds |
| US20070066920A1 (en) * | 2002-06-14 | 2007-03-22 | Hemcon Medical Technologies, Inc. | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
| GB2393655B (en) * | 2002-09-27 | 2005-08-24 | Johnson & Johnson Medical Ltd | Wound treatment device |
| DE10252725A1 (de) * | 2002-11-13 | 2004-06-03 | Lts Lohmann Therapie-Systeme Ag | Feuchtigkeitsaktivierbare Klebstoffe für medizinische Anwendungszwecke |
| WO2005035010A1 (en) * | 2003-10-10 | 2005-04-21 | Coloplast A/S | Wound dressing containing proteolytic enzymes |
| US20060188486A1 (en) * | 2003-10-14 | 2006-08-24 | Medivas, Llc | Wound care polymer compositions and methods for use thereof |
| RU2240830C1 (ru) * | 2003-12-26 | 2004-11-27 | ФГУП Государственный научно-исследовательский институт особо чистых биопрепаратов | Раневое покрытие и способ его получения |
| DE102004022645A1 (de) * | 2004-05-07 | 2005-12-15 | Resorba Wundversorgung Gmbh & Co. Kg | Bioresorbierbares Material auf Kollagen-Basis |
| US20060134307A1 (en) * | 2004-12-20 | 2006-06-22 | Unilever Bestfoods, North America, Division Of Conopco, Inc. | Starch comprising and ready-to-serve ambient stable fruit-based composition |
| GB2433263A (en) * | 2005-12-15 | 2007-06-20 | Ethicon Inc | Antimicrobial polyurethane foam |
-
2009
- 2009-08-28 US US12/550,045 patent/US20100055158A1/en not_active Abandoned
- 2009-08-28 AU AU2009286021A patent/AU2009286021B2/en not_active Ceased
- 2009-08-28 EP EP09810382.3A patent/EP2323703A4/en not_active Withdrawn
- 2009-08-28 CN CN2009801390187A patent/CN102170916A/zh active Pending
- 2009-08-28 WO PCT/US2009/004908 patent/WO2010024928A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050049182A1 (en) * | 2001-08-21 | 2005-03-03 | Micrologix Biotech Inc. | Antimicrobial cationic peptides and formulations thereof |
| CN101252905A (zh) * | 2005-07-15 | 2008-08-27 | 泰科保健集团有限合伙公司 | 伤口敷料和制造及使用其的方法 |
| US20070237812A1 (en) * | 2006-04-11 | 2007-10-11 | Tyco Healthcare Group | Multi-layer wound dressings |
| US20080063695A1 (en) * | 2006-09-12 | 2008-03-13 | Tyco Healthcare Group Lp | Thin film dressing |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111432761A (zh) * | 2017-11-03 | 2020-07-17 | 凯希特许有限公司 | 延长穿戴时间的敷料 |
| CN111432761B (zh) * | 2017-11-03 | 2022-09-09 | 3M创新知识产权公司 | 延长穿戴时间的敷料 |
| CN108853590A (zh) * | 2018-08-22 | 2018-11-23 | 上海长海医院 | 一种人工真皮 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2323703A1 (en) | 2011-05-25 |
| AU2009286021B2 (en) | 2014-07-17 |
| AU2009286021A1 (en) | 2010-03-04 |
| EP2323703A4 (en) | 2013-11-20 |
| US20100055158A1 (en) | 2010-03-04 |
| WO2010024928A1 (en) | 2010-03-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102170916A (zh) | 环境活化的组合物，制品与方法 | |
| US20220273495A1 (en) | Multi-Layer Wound Care Device Having Absorption and Fluid Transfer Properties | |
| US20220265893A1 (en) | Wound care device having fluid transfer and adhesive properties | |
| US20220184269A1 (en) | Wound care device having fluid transfer and adhesive properties | |
| US20190358361A1 (en) | Wound dressing with apertured cover sheet | |
| US8021685B2 (en) | Wound care device having fluid transfer properties | |
| EP3061467B1 (en) | Wound dressing with a bacterial adsorbing composition | |
| AU2004248898B2 (en) | Antimicrobial wounddressing | |
| US20100030170A1 (en) | Absorptive Pad | |
| JP5853019B2 (ja) | 創傷被覆材 | |
| MXPA05003802A (es) | Vendaje medico que contiene un agente antimicrobiano. | |
| CN109568009A (zh) | 可延伸的敷料 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110831 |